PH-ILD Market on Track for Major Expansion by 2034, According to DelveInsigh | Insmed Incorporated, Bellerophon Therapeutics, United Therapeutics, Bayer, Biogen

The Key PH-ILD Companies in thr market include - United Therapeutics Corp., Insmed Incorporated, Bellerophon Therapeutics, United Therapeutics, Bayer, Biogen, and others.

DelveInsight's "Pulmonary Hypertension Associated with Interstitial Lung Disease Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Pulmonary Hypertension Associated with Interstitial Lung Disease, historical and forecasted epidemiology as well as the Pulmonary Hypertension Associated with Interstitial Lung Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the PH-ILD market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; PH-ILD Market Forecast [https://www.delveinsight.com/sample-request/pulmonary-hypertension-associated-with-interstitial-lung-disease-ph-ild-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Pulmonary Hypertension Associated with Interstitial Lung Disease Market Report:

*
The PH-ILD market size was valued approximately USD 1,400 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

*
In 2023, the PH-ILD market size in the United States among the 7MM was estimated at approximately USD 1,100 million. This market is projected to experience substantial growth by 2034, driven by factors such as rising awareness, advancements in treatment options, and an increasing elderly population.

*
The PH-ILD market is currently led by a range of treatments, including TYVASO/TYVASO DPI (treprostinil), diuretics, endothelin receptor antagonists (ERAs), phosphodiesterase type 5 inhibitors (PDE-5is), corticosteroids, and others. Among these, endothelin receptor antagonists (ERAs) hold the largest market share, generating nearly USD 800 million in revenue across the 7MM in 2023.

*
In 2023, the PH-ILD market in the EU4 and the UK was valued at approximately USD 200 million, with projections indicating growth by 2034.

*
In 2023, the total diagnosed prevalent cases of PH-ILD in the 7MM were approximately 172,000, with numbers projected to increase by 2034.

*
Among the 7MM, the United States recorded the highest number of diagnosed prevalent cases of PH-ILD, reaching approximately 92,000 in 2023.

*
In 2023, the EU4 and the UK reported approximately 58,000 diagnosed prevalent cases of PH-ILD, with numbers expected to rise by 2034. Among these countries, Germany had the highest prevalence with around 14,000 cases, followed by the UK with 13,000 cases. In contrast, Spain had the lowest diagnosed prevalent population, with approximately 9,000 cases, the same as another country in the region.

*
Among the type-specific diagnosed prevalent cases of PH-ILD in 2023, idiopathic interstitial pneumonia (IIP) had the highest prevalence in the US, with approximately 54,000 cases, followed by autoimmune ILD, which accounted for around 32,000 cases.

*
Key PH-ILD Companies: United Therapeutics Corp., Insmed Incorporated, Bellerophon Therapeutics, United Therapeutics, Bayer, Biogen, and others

*
Key PH-ILD Therapies: TYVASO/TYVASO DPI (treprostinil), TPIP, INOpulse, Inhaled Treprostinil, Riociguat (Adempas, BAY63-2521), Bardoxolone methyl, and others

*
The PH-ILD market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Pulmonary Hypertension Associated with Interstitial Lung Disease pipeline products will significantly revolutionize the Pulmonary Hypertension Associated with Interstitial Lung Disease market dynamics.

PH-ILD Overview

An elevated pulmonary arterial pressure (PAP) of many etiologies that can cause significant morbidity is known as pulmonary hypertension (PH), a significant consequence of interstitial lung disease (ILD). The World Symposium on PH defined five clinical groups for PH based on differences in pathological findings among the groups, such as the underlying cause of the disease, clinical presentation, and hemodynamic features.

Get a Free sample for the Pulmonary Hypertension Associated with Interstitial Lung Disease Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/pulmonary-hypertension-associated-with-interstitial-lung-disease-ph-ild-market [https://www.delveinsight.com/report-store/pulmonary-hypertension-associated-with-interstitial-lung-disease-ph-ild-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Pulmonary Hypertension Associated with Interstitial Lung Disease Epidemiology

The Pulmonary Hypertension Associated with Interstitial Lung Disease epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Pulmonary Hypertension Associated with Interstitial Lung Disease Epidemiology Segmentation:

The Pulmonary Hypertension Associated with Interstitial Lung Disease market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

*
Total Prevalence of PH-ILD

*
Prevalent Cases of PH-ILD by severity

*
Gender-specific Prevalence of PH-ILD

*
Diagnosed Cases of Episodic and Chronic PH-ILD

Download the report to understand which factors are driving PH-ILD epidemiology trends @ Pulmonary Hypertension Associated with Interstitial Lung Disease Epidemiology Forecast [https://www.delveinsight.com/sample-request/pulmonary-hypertension-associated-with-interstitial-lung-disease-ph-ild-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Pulmonary Hypertension Associated with Interstitial Lung Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Pulmonary Hypertension Associated with Interstitial Lung Disease market or expected to get launched during the study period. The analysis covers Pulmonary Hypertension Associated with Interstitial Lung Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Pulmonary Hypertension Associated with Interstitial Lung Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Pulmonary Hypertension Associated with Interstitial Lung Disease Therapies and Key Companies

*
TYVASO/TYVASO DPI (treprostinil): United Therapeutics Corp.

*
Treprostinil Palmitil: Insmed Incorporated

*
TPIP: Insmed Incorporated

*
INOpulse: Bellerophon Therapeutics

*
Inhaled Treprostinil: United Therapeutics

*
Riociguat (Adempas, BAY63-2521): Bayer

*
Bardoxolone methyl: Biogen

Discover more about therapies set to grab major Pulmonary Hypertension Associated with Interstitial Lung Disease market share @ Pulmonary Hypertension Associated with Interstitial Lung Disease Treatment Landscape [https://www.delveinsight.com/sample-request/pulmonary-hypertension-associated-with-interstitial-lung-disease-ph-ild-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

PH-ILD Market Drivers

*
The worldwide population and improvement in diagnosis are resulting in a rise in PH prevalence associated with several types of ILDs. This rise in cases is supposed to strengthen the market in the future.

*
Treatment demand for PH-ILD is increasing, with a lack of therapies to manage the disease burden. Hence, the market is vast and up for any key player developing a novel therapy.

PH-ILD Market Barriers

*
Expected approval of potential therapies can increase market size.

*
Lucrative opportunities for market growth in the studied countries, owing to the presence of a large pool of patients suffering from PH-ILD

Scope of the PH-ILD Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Pulmonary Hypertension Associated with Interstitial Lung Disease Companies: United Therapeutics Corp., Insmed Incorporated, Bellerophon Therapeutics, United Therapeutics, Bayer, Biogen, and others

*
Key Pulmonary Hypertension Associated with Interstitial Lung Disease Therapies: TYVASO/TYVASO DPI (treprostinil), TPIP, INOpulse, Inhaled Treprostinil, Riociguat (Adempas, BAY63-2521), Bardoxolone methyl, and others

*
Pulmonary Hypertension Associated with Interstitial Lung Disease Therapeutic Assessment: Pulmonary Hypertension Associated with Interstitial Lung Disease current marketed and Pulmonary Hypertension Associated with Interstitial Lung Disease emerging therapies

*
Pulmonary Hypertension Associated with Interstitial Lung Disease Market Dynamics: Pulmonary Hypertension Associated with Interstitial Lung Disease market drivers and Pulmonary Hypertension Associated with Interstitial Lung Disease market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Pulmonary Hypertension Associated with Interstitial Lung Disease Unmet Needs, KOL's views, Analyst's views, Pulmonary Hypertension Associated with Interstitial Lung Disease Market Access and Reimbursement

To know more about Pulmonary Hypertension Associated with Interstitial Lung Disease companies working in the treatment market, visit @ PH-ILD Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/pulmonary-hypertension-associated-with-interstitial-lung-disease-ph-ild-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Pulmonary Hypertension Associated with Interstitial Lung Disease Market Report Introduction

2. Executive Summary for Pulmonary Hypertension Associated with Interstitial Lung Disease

3. SWOT analysis of Pulmonary Hypertension Associated with Interstitial Lung Disease

4. Pulmonary Hypertension Associated with Interstitial Lung Disease Patient Share (%) Overview at a Glance

5. Pulmonary Hypertension Associated with Interstitial Lung Disease Market Overview at a Glance

6. Pulmonary Hypertension Associated with Interstitial Lung Disease Disease Background and Overview

7. Pulmonary Hypertension Associated with Interstitial Lung Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Pulmonary Hypertension Associated with Interstitial Lung Disease

9. Pulmonary Hypertension Associated with Interstitial Lung Disease Current Treatment and Medical Practices

10. Pulmonary Hypertension Associated with Interstitial Lung Disease Unmet Needs

11. Pulmonary Hypertension Associated with Interstitial Lung Disease Emerging Therapies

12. Pulmonary Hypertension Associated with Interstitial Lung Disease Market Outlook

13. Country-Wise Pulmonary Hypertension Associated with Interstitial Lung Disease Market Analysis (2020-2034)

14. Pulmonary Hypertension Associated with Interstitial Lung Disease Market Access and Reimbursement of Therapies

15. Pulmonary Hypertension Associated with Interstitial Lung Disease Market Drivers

16. Pulmonary Hypertension Associated with Interstitial Lung Disease Market Barriers

17. Pulmonary Hypertension Associated with Interstitial Lung Disease Appendix

18. Pulmonary Hypertension Associated with Interstitial Lung Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=phild-market-on-track-for-major-expansion-by-2034-according-to-delveinsigh-insmed-incorporated-bellerophon-therapeutics-united-therapeutics-bayer-biogen]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.